Eribulin Mesylate for Pelvic Neoplasms
Study Summary
This trial is testing atezolizumab with or without eribulin mesylate to see if it can help people with urothelial cancer that has come back or spread to other parts of the body.
- Pelvic Neoplasms
- Metastatic Ureter Urothelial Carcinoma
- Renal pelvis
- Metastatic Renal Pelvis Urothelial Carcinoma
- Ureter
- Locally Advanced Ureter Urothelial Carcinoma
- Urinary Bladder
- Malignant neoplasm of ureter
- Stage III Urethral Cancer AJCC v7
- Unresectable Urethral Urothelial Carcinoma
- Stage IV Ureter Cancer AJCC v7
- Metastatic Urethral Urothelial Carcinoma
- Stage IV Urethral Cancer AJCC v7
- Locally Advanced Urethral Urothelial Carcinoma
- Malignant Neoplasms
- Recurrent Urethral Urothelial Carcinoma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
3 Primary · 6 Secondary · Reporting Duration: Up to 52 weeks
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Arm II (atezolizumab, eribulin mesylate)
1 of 2
Arm I (atezolizumab)
1 of 2
Experimental Treatment
72 Total Participants · 2 Treatment Groups
Primary Treatment: Eribulin Mesylate · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 11th, 2021
Last Reviewed: November 13th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.